226 related articles for article (PubMed ID: 24801480)
1. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,(®)/Doxil(®)--a cerebral open flow microperfusion pilot study.
Birngruber T; Raml R; Gladdines W; Gatschelhofer C; Gander E; Ghosh A; Kroath T; Gaillard PJ; Pieber TR; Sinner F
J Pharm Sci; 2014 Jul; 103(7):1945-1948. PubMed ID: 24801480
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
Gaillard PJ; Appeldoorn CC; Dorland R; van Kregten J; Manca F; Vugts DJ; Windhorst B; van Dongen GA; de Vries HE; Maussang D; van Tellingen O
PLoS One; 2014; 9(1):e82331. PubMed ID: 24416140
[TBL] [Abstract][Full Text] [Related]
3. Cerebral open flow microperfusion: a new in vivo technique for continuous measurement of substance transport across the intact blood-brain barrier.
Birngruber T; Ghosh A; Perez-Yarza V; Kroath T; Ratzer M; Pieber TR; Sinner F
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):864-71. PubMed ID: 24256164
[TBL] [Abstract][Full Text] [Related]
4. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cerebral Open Flow Microperfusion and Microdialysis when sampling small lipophilic and small hydrophilic substances.
Altendorfer-Kroath T; Schimek D; Eberl A; Rauter G; Ratzer M; Raml R; Sinner F; Birngruber T
J Neurosci Methods; 2019 Jan; 311():394-401. PubMed ID: 30266621
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
7. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
[TBL] [Abstract][Full Text] [Related]
8. Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats.
Rip J; Chen L; Hartman R; van den Heuvel A; Reijerkerk A; van Kregten J; van der Boom B; Appeldoorn C; de Boer M; Maussang D; de Lange EC; Gaillard PJ
J Drug Target; 2014 Jun; 22(5):460-7. PubMed ID: 24524555
[TBL] [Abstract][Full Text] [Related]
9. Applicability of cerebral open flow microperfusion and microdialysis to quantify a brain-penetrating nanobody in mice.
Custers ML; Wouters Y; Jaspers T; De Bundel D; Dewilde M; Van Eeckhaut A; Smolders I
Anal Chim Acta; 2021 Sep; 1178():338803. PubMed ID: 34482878
[TBL] [Abstract][Full Text] [Related]
10. Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model.
Aryal M; Park J; Vykhodtseva N; Zhang YZ; McDannold N
Phys Med Biol; 2015 Mar; 60(6):2511-27. PubMed ID: 25746014
[TBL] [Abstract][Full Text] [Related]
11. Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study.
Lindqvist A; Rip J; Gaillard PJ; Björkman S; Hammarlund-Udenaes M
Mol Pharm; 2013 May; 10(5):1533-41. PubMed ID: 22934681
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
13. The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre-insertion and post-insertion methods for brain delivery in normal mice.
Mehrabian A; Dadpour S; Mashreghi M; Zarqi J; Askarizadeh A; Badiee A; Arabi L; Moosavian SA; Jaafari MR
IET Nanobiotechnol; 2023 Apr; 17(2):112-124. PubMed ID: 36594666
[TBL] [Abstract][Full Text] [Related]
14. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
15. Cerebral Open Flow Microperfusion to Monitor Drug Transport Across the Blood-Brain Barrier.
Hummer J; Altendorfer-Kroath T; Birngruber T
Curr Protoc Pharmacol; 2019 Jun; 85(1):e60. PubMed ID: 31145555
[TBL] [Abstract][Full Text] [Related]
16. Glutathione conjugation dose-dependently increases brain-specific liposomal drug delivery in vitro and in vivo.
Maussang D; Rip J; van Kregten J; van den Heuvel A; van der Pol S; van der Boom B; Reijerkerk A; Chen L; de Boer M; Gaillard P; de Vries H
Drug Discov Today Technol; 2016 Jun; 20():59-69. PubMed ID: 27986226
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
Jiang W; Lionberger R; Yu LX
Bioanalysis; 2011 Feb; 3(3):333-44. PubMed ID: 21320053
[TBL] [Abstract][Full Text] [Related]
18. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
20. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
